Erlotinib News and Research

RSS

Erlotinib is a drug used to treat certain types of non-small cell lung cancer. It is also used together with gemcitabine to treat pancreatic cancer and is being studied in the treatment of other types of cancer. Erlotinib is a type of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor. Also called CP-358,774, erlotinib hydrochloride, OSI-774, and Tarceva.

Boehringer Ingelheim LUX-Lung 8 trial reveals afatinib better than erlotinib to treat SCC of the lung

Boehringer Ingelheim today announced The Lancet Oncology has published results from the LUX-Lung 8 trial. LUX-Lung 8 is the largest, prospective Phase III head-to-head trial directly comparing two EGFR-directed treatments.

6 Jul 2015

BerGenBio begins BGB324 Phase 1b trial in combination with erlotinib in NSCLC patients

BerGenBio AS, an oncology biopharmaceutical company, today announces that its multi-centre open label Phase 1b trial (BGBC004) of BGB324, a selective inhibitor of Axl, in patients with Stage IIIb and Stage IV non-small cell lung cancer (NSCLC) in erlotinib-sensitive and refractory patients who have an activating EGFR mutation, is now underway at the University of Texas MD Anderson Cancer Center, Houston, Oncology Partners, Houston, and at UT Southwestern Medical Center, Dallas, Texas, USA.

10 Jun 2015

Boehringer Ingelheim presents afatinib LUX-Lung 8 trial data at ASCO 2015

2 Jun 2015

AstraZeneca announces efficacy and safety data for AZD9291 in first-line treatment of EGFRm advanced NSCLC

AstraZeneca today announced preliminary efficacy and safety data for AZD9291 in the first-line treatment of epidermal growth factor receptor mutation positive (EGFRm) advanced non-small cell lung cancer (NSCLC).

2 Jun 2015

New data underscores the importance of FoundationOne genomic profiling for treatment of biliary tract cancers

Foundation Medicine, Inc. today presented new data including promising clinical outcomes underscoring the importance of integrating comprehensive genomic profiling with FoundationOne® into clinical oncology care for the treatment of biliary tract cancers.

2 Jun 2015

Boehringer announces LUX-Lung 8 data that compares efficacy of afatinib, erlotinib in patients with advanced SCC

Boehringer Ingelheim today announced overall survival (OS) results from the LUX-Lung 8 trial (NCT01523587) that directly compared the efficacy and safety of two EGFR-directed treatments, afatinib and erlotinib, in patients with advanced squamous cell carcinoma (SCC) of the lung, progressing after treatment with first-line chemotherapy. Treatment with afatinib significantly reduced the risk of death by 19%, extending the survival of patients to a median of 7.9 months compared to 6.8 months on erlotinib.

1 Jun 2015

Clinical utility of Caris Molecular Intelligence in five studies to be presented at ASCO 2015

Caris Life Sciences, a leading biotechnology company focused on fulfilling the promise of precision medicine, today announced the presentation of data from five studies that demonstrate the clinical utility of Caris Molecular Intelligence®, the company's panomic comprehensive tumor profiling service, in helping to identify targeted treatment options for patients with rare and/or aggressive tumors.

1 Jun 2015

Stanford University professor named recipient of 2015 ECOG-ACRIN Young Investigator Award

Heather Wakelee, MD, is the recipient of the 2015 ECOG-ACRIN Young Investigator Award, the ECOG-ACRIN Cancer Research Group announced today. Dr. Wakelee is associate professor of medicine in the Division of Oncology at the Stanford University School of Medicine in Stanford, Calif.

7 May 2015

Researchers identify multiple types of resistance to new targeted lung cancer drug

After identifying three different types of resistance to a promising investigational lung cancer drug in a phase 1 trial, a team of researchers led by Dana-Farber Cancer Institute scientists say new targeted inhibitors and combinations are urgently needed to stay ahead of tumors' constant and varied molecular shape-shifting.

5 May 2015

Plasma EGFR mutation cfDNA predicts advanced lung cancer outcome

Monitoring plasma cell-free DNA levels of epidermal growth factor receptor mutations may indicate prognosis for patients with lung adenocarcinoma after EGFR–tyrosine kinase inhibitor therapy, research suggests.

28 Jan 2015

Rare, complex EGFR mutations adversely affect EGFR–TKI treatment outcomes

Individuals with advanced non-small-cell lung cancer who have rare or complex epidermal growth factor receptor mutations have inferior outcomes in response to EGFR–tyrosine kinase inhibitor treatment compared with those with common mutations, research indicates.

20 Jan 2015

New treatment approach may improve survival rates for certain patients with stage 4 lung cancer

A clinical trial that combined stereotactic body radiation therapy with a specific chemotherapy regimen more than doubled survival rates for certain stage 4 lung cancer patients, UT Southwestern Medical Center cancer researchers report.

2 Jan 2015

Preclinical study strongly supports NT-113 as potential new treatment for glioblastoma multiforme

NewGen Therapeutics, Inc. today announced the publication of preclinical research strongly supporting NT-113, the company's novel irreversible pan-erbB inhibitor (EGFR, HER2 and HER4), as a potential new treatment for glioblastoma multiforme (GBM), the most common and most aggressive malignant primary brain tumor in adults.

16 Dec 2014

Figitumumab development discontinued for non-adenocarcinoma NSCLC

Adding the novel insulin-like growth factor 1 receptor inhibitor figitumumab to the epidermal growth factor receptor–tyrosine kinase inhibitor erlotinib does not improve survival in patients with non-adenocarcinoma non-small-cell lung carcinoma, research shows.

12 Dec 2014

First-line dacomitinib may improve advanced NSCLC survival

Preliminary research suggests that the second-generation tyrosine kinase inhibitor dacomitinib may improve progression-free survival in patients with advanced non-small-cell lung cancer with epidermal growth factor receptor mutations.

11 Dec 2014

PD-1, PD-L1 differentially expressed in NSCLC

The expression of the immune checkpoint protein programmed death-1 receptor and its ligand varies according to tumour and patient characteristics in oncogene-addicted non-small-cell lung cancer, research indicates.

9 Dec 2014

Commonly used osteoporosis medications may also prevent lung, breast and colon cancers

The most commonly used medications for osteoporosis worldwide, bisphosphonates, may also prevent certain kinds of lung, breast and colon cancers, according to two studies led by researchers at the Icahn School of Medicine at Mount Sinai and published today in the Proceedings of the National Academy of Sciences.

2 Dec 2014

Dacomitinib ‘not superior’ to erlotinib in advanced NSCLC

Dacomitinib, an irreversible, pan-epidermal growth factor receptor tyrosine kinase inhibitor, does not improve outcomes compared with the first-generation EGFR–TKI erlotinib in patients with advanced non-small-cell lung cancer, irrespective of their KRAS mutation status, finds the ARCHER 1009 study.

24 Nov 2014

New drug shows promise against treatment-resistant non-small cell lung cancer

A new drug that targets not only common cancer-causing genetic mutations in patients with non-small cell lung cancer (NSCLC), but also a form of the mutation that causes resistance to treatment, has shown promising results in patients in a phase I/II clinical trial.

23 Nov 2014

No survival benefit with dacomitinib in pretreated patients with advanced NSCLC

The irreversible, pan-epidermal growth factor receptor tyrosine kinase inhibitor dacomitinib does not offer a survival benefit in pretreated patients with advanced or metastatic non-small-cell lung cancer, phase III trial results show.

14 Nov 2014

Erlotinib News and Research

Boehringer Ingelheim LUX-Lung 8 trial reveals afatinib better than erlotinib to treat SCC of the lung

BerGenBio begins BGB324 Phase 1b trial in combination with erlotinib in NSCLC patients

Boehringer Ingelheim presents afatinib LUX-Lung 8 trial data at ASCO 2015

AstraZeneca announces efficacy and safety data for AZD9291 in first-line treatment of EGFRm advanced NSCLC

New data underscores the importance of FoundationOne genomic profiling for treatment of biliary tract cancers

Boehringer announces LUX-Lung 8 data that compares efficacy of afatinib, erlotinib in patients with advanced SCC

Clinical utility of Caris Molecular Intelligence in five studies to be presented at ASCO 2015

Stanford University professor named recipient of 2015 ECOG-ACRIN Young Investigator Award

Researchers identify multiple types of resistance to new targeted lung cancer drug

Plasma EGFR mutation cfDNA predicts advanced lung cancer outcome

Rare, complex EGFR mutations adversely affect EGFR–TKI treatment outcomes

New treatment approach may improve survival rates for certain patients with stage 4 lung cancer

Preclinical study strongly supports NT-113 as potential new treatment for glioblastoma multiforme

Figitumumab development discontinued for non-adenocarcinoma NSCLC

First-line dacomitinib may improve advanced NSCLC survival

PD-1, PD-L1 differentially expressed in NSCLC

Commonly used osteoporosis medications may also prevent lung, breast and colon cancers

Dacomitinib ‘not superior’ to erlotinib in advanced NSCLC

New drug shows promise against treatment-resistant non-small cell lung cancer

No survival benefit with dacomitinib in pretreated patients with advanced NSCLC

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech

Latest News